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Abstract
MR‐only treatment planning and MR‐IGRT leverage MRI's powerful soft tissue con-
trast for high‐precision radiation therapy. However, anthropomorphic MR‐compatible
phantoms are currently limited. This work describes the development and evaluation
of a custom‐designed, modular, pelvic end‐to‐end (PETE) MR‐compatible phantom to
benchmark MR‐only and MR‐IGRT workflows. For construction considerations, sub-
ject data were assessed for phantom/skeletal geometry and internal organ kinematics
to simulate average male pelvis anatomy. Various materials for the bone, bladder, and
rectum were evaluated for utility within the phantom. Once constructed, PETE under-
went CT‐SIM, MR‐Linac, and MR‐SIM imaging to qualitatively assess organ visibility.
Scans were acquired with various bladder and rectal volumes to assess component
interactions, filling capabilities, and filling reproducibility via volume and centroid dif-
ferences. PETE simulates average male pelvis anatomy and comprises an acrylic body
oval (height/width = 23.0/38.1 cm) and a cast‐mold urethane skeleton, with silicone
balloons simulating bladder and rectum, a silicone sponge prostate, and hydrophilic
poly(vinyl alcohol) foam to simulate fat/tissue separation between organs. Access ports
enable retrofitting the phantom with other inserts including point/film‐based dosimetry
options. Acceptable contrast was achievable in CT‐SIM and MR‐Linac images. How-
ever, the bladder was challenging to distinguish from background in CT-SIM. The
desired contrast for T1‐weighted and T2‐weighted MR‐SIM (dark and bright bladders,
respectively) was achieved. Rectum and bone exhibited no MR signal. Inputted vol-
umes differed by <5 and <10 mL from delineated rectum (CT‐SIM) and bladder (MR‐
SIM) volumes. Increasing bladder and rectal volumes induced organ displacements and
shape variations. Reproduced volumes differed by <4.5 mL, with centroid displace-
ments <1.4 mm. A point dose measurement with an MR‐compatible ion chamber in an
MR‐Linac was within 1.5% of expected. A novel, modular phantom was developed
with suitable materials and properties that accurately and reproducibly simulate status
changes with multiple dosimetry options. Future work includes integrating more realis-
tic organ models to further expand phantom options.
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K E Y WORD S
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1 | INTRODUCTION
Radiation therapy (RT) treatments are traditionally planned using
computed‐tomography simulation (CT‐SIM) images, with interfraction
patient setup verification performed using x‐ray‐based on‐board (OB)
imaging techniques. Although CT offers strengths such as providing
a direct measurement of electron density for dose calculation and
geometric image accuracy, it lacks the excellent soft tissue contrast
achievable from magnetic resonance imaging (MRI).1 In the male pel-
vis, MRI has been shown to improve prostate delineation accuracy,2–
5 reduce interobserver contouring variability,3–6 improve the localiza-
tion of the prostate apex,2–6 and increase differentiation of the semi-
nal vesicles from the base of the prostate.2,4,6 Consequently,
treatment planning using MR/CT coregistered images, where delin-
eated soft tissue structures on MR images are transferred onto fused
CT images, is often utilized.2,6 However, uncertainties on the order
of 2 mm are introduced due to this coregistration in the pelvis7,8
that may be reduced with MR‐only radiation treatment planning.9
MR‐only treatment planning eliminates this coregistration uncer-
tainty while streamlining clinical efficiency.
Furthermore, the implementation of on‐board MR image‐guided
radiation therapy (IGRT) systems allows for daily image guidance and
real‐time imaging throughout a treatment fraction, which is ideal for
managing and monitoring both interfraction and intrafraction motion,
respectively, without additional radiation exposure.10,11 It has been
shown that critical structures and targets within the pelvis are better
visualized on MR‐IGRT systems than OB‐CT,10 allowing for superior
target localization. This, in turn, may lead to improved accuracy of
MR‐to‐MR registration and facilitate dose escalation while also offer-
ing potential to reduce treatment margins and toxicity to organs at
risk.11
However, MRI and MR simulation (MR‐SIM) acquisitions typically
require longer scanning times than CT, which may result in additional
errors being introduced because of anatomical or patient move-
ment.12 In the pelvis, multiple uncertainties may arise as a result of
patient motion, changes in anatomical structure (position/deforma-
tion) due to intrasession bladder filling, and the introduction of
patient‐specific distortions due to air in the rectum.13 Because of
this transient nature, it is currently difficult to characterize the geo-
metric and dosimetric uncertainties that may arise in these new
workflows. MR‐compatible phantoms are currently limited for bench-
marking these new workflows. Recently, an anthropomorphic multi-
modality prostate phantom was developed to compare MR‐SIM to
CT‐SIM.14 The phantom was custom designed with organs (prostate,
rectum, bladder, and femoral heads) that adequately generated signal
in MR for end‐to‐end testing. However, it was unable to simulate
organ filling. Niebuhr et al. performed a thorough material evaluation
to create a deformable male pelvic phantom to study adaptive
treatment scenarios in MR‐IGRT15 with the ability to induce volume
variations in both the bladder and rectum. However, sodium salt‐
loaded gels used to mimic soft tissue attenuation properties induced
severe MR artifacts. In general, these phantoms met their individual
design goals but lacked the ability to perform dosimetric verification
as required to benchmark MR‐IGRT or MR‐only workflows.
This work describes the development of a novel pelvic end‐to‐
end (PETE) MR‐compatible phantom that meets the design goals of
benchmarking both MR‐only treatment planning and MR‐IGRT
workflows. The phantom is anthropomorphic and modular and
enables dosimetric validation. Furthermore, the phantom can simu-
late different physiological status conditions and may be used to
quantify the uncertainties introduced in both MR‐only and MR‐
IGRT workflows.
2 | MATERIALS AND METHODS
2.A | Phantom geometry
Phantom outer dimensions were determined via retrospective evalu-
ation of axial MR‐SIM T2‐weighted (T2W) Turbo‐Spin‐Echo (TSE)
data for 19 prostate cancer patients under an IRB‐approved study.
Patients were positioned supine and head‐first, aligned using external
LAP lasers (LAP GmbH Laser Applications, Lüneberg, Germany) to
right central axis (CAX), left CAX, and anterior CAX tattoos. They
were immobilized with their hands placed on chest, feet banded, and
knees immobilized in a black leg sponge. The phantom habitus was
determined by evaluating data taken in treatment position at the
marked isocenter across the cohort. Measurements of the pelvis
width, pelvis height, and sacrum external spacing (distance between
the posterior edge of the sacrum and the exterior body surface)
were taken using the distance measurement tool in the Eclipse
Treatment Planning System (Varian Medical Systems, Palo Alto, CA).
Because of the high visibility of the pelvic bones in the CT‐SIM data-
set, the pelvic skeleton dimensions across the same 19 subjects were
also determined using the treatment planning CT for each patient.
Measurements for the iliac crest width, femoral head width, greater
trochanter width, pelvic skeleton depth, and pelvic skeleton height
were also obtained using the distance measurement tool in Eclipse.
2.B | Internal organ kinematics
To quantify the impact of systematic bladder filling on organ volume,
location, and displacement, 10 immobilized healthy volunteers under-
went a ~45‐min MR‐SIM imaging session using the bladder filling
protocol outlined in Fig. 1. Subjects voided their bladder prior to
consuming 600 mL of water, T2W sequences were acquired immedi-
ately with empty bladders and ~15 min postconsumption with
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partially full bladders. An additional 300–600 mL of water were con-
sumed with no subject repositioning, and one to two more time
points were acquired with full bladders. A single physician delineated
the bladder and rectum at each time point following RTOG 0815 cri-
teria.16 Temporal datasets were evaluated for the center of mass,
shape, and volume of the rectum and bladder with varied filling con-
ditions. To characterize the rectum shape, measurements were
obtained as shown in Fig. 2(a) for the width of the anterior, poste-
rior, and middle of the rectum, the length, and the distance from the
coccyx to the posterior of the rectum.
2.C | Phantom materials
2.C.1 | Bladder considerations
Two medical balloon catheter assemblies, a 600‐mL maximum inter-
nal volume polyisoprene balloon (#CBL7P, Mui Scientific) and a 300‐
mL maximum internal volume silicone balloon (#BM‐300‐2, Mui Sci-
entific) were evaluated for preliminary material evaluation for simu-
lating bladder status changes. The polyisoprene balloon was filled
with distilled water using a 20‐mL syringe to increasing volumes up
to 350 mL while the silicone balloon was filled to 250 mL and
imaged in a 1.0‐T Panorama High‐Field Open (HFO) system (Philips
Medical Systems, Best, the Netherlands). The general shape, long‐
term stability, and filling capacity of each of these balloon assemblies
were assessed. To evaluate the potential of filling the silicone bal-
loon to >300 mL, the filling integrity was assessed by filling it
repeatedly to 500 mL and visually inspecting the balloon for
mechanical/physical changes.
2.C.2 | Bone considerations
Two candidate custom pelvic skeletons produced by Stratasys
(Stratasys Ltd., Eden Prairie, MN) were custom cast in WC‐788
(clear) and PT8957 (blue) urethane material using average male pel-
vic geometry, with densities of 1.10 and 1.25 g/mL, respectively.
Both pelvises underwent imaging in a Brilliance Big Bore (Philips
Health Care, Cleveland, OH) CT‐SIM and a Philips 1.0‐T High‐Field
Open (HFO) MR‐SIM. Because cortical bone exhibits short T2 and
T2* properties, it is typically undetectable in MRI. However,
improved visibility is achieved through the utilization of ultra‐short
echo time (UTE) sequences.17 Therefore, both pelvises were imaged
using a UTE‐Dixon sequence (repetition time (TR)/echo time (TE)/flip
F I G . 1 . Bladder filling protocol: the patient originally voided their bladder then consumed ~600 mL of water. A T2W MR‐SIM scan was
acquired immediately after drinking and 15 min later. After which, the subject consumed an additional 300–600 mL of water and was imaged
again a total of 30 min after the initial bladder void. A 3D modeling is shown for each time point, where a much larger longitudinal than lateral
growth of the bladder is observed.
F I G . 2 . Rectum dimension
measurements: (a) visually demonstrates
the growth and positioning of the bladder
throughout the bladder filling protocol. The
initial and final bladder volumes are
contoured in blue and yellow, respectively,
while the initial and final rectums are
contoured in green and brown,
respectively. The corresponding initial and
final rectum measurements demonstrated
in (a) are shown in (b), where a larger
rectum length was observed than width.
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angle (α) = 11.5/(0.14/3.45/6.9) ms/25°, voxel size = 0.96 × 0.96 ×
1.3 mm3, and bandwidth = 994 Hz/pixel) to determine if any mea-
surable signal was detected.
2.D | Phantom evaluation
2.D.1 | Scan acquisition
The final phantom build was evaluated across three platforms. CT images
were acquired using a Philips Brilliance Big Bore CT‐SIM with the follow-
ing settings: 120 kVp, 244 mAs, 512 × 512 mm2 field of view (FOV),
0.98 × 0.98 mm2 resolution, and 2.0‐mm slice thickness. To ensure con-
sistent positioning within each imaging modality, the phantom was
aligned via external LAP lasers to the external markings (anterior CAX,
left CAX, and right CAX) made during CT‐SIM. MR images were acquired
on the MRIdian Linac (ViewRay Inc., Oakwood Village, OH) using a true
fast imaging and steady precession (TrueFISP) sequence. This is a fully
refocused (refocusing occurs in all three axes) steady‐state sequencewith
shorter acquisition time, high contrast‐to‐noise, and signal‐to‐noise
ratios.18 Two 12‐element phased array coils were used for imaging the
phantom. A 173‐s scan, with a 45 × 30 × 36 cm3 FOV, and
0.15 × 0.15 cm2 resolution was acquired.
The MR‐SIM images were acquired using the 1.0‐T MR‐SIM
equipped with a flat tabletop using a large, rigid eight‐element
phased array coil. Three sequences were acquired: an axial three‐
dimensional (3D) T1‐weighted (T1W) fast field echo sequence (TR/
TE/α = 17.7/6.9 ms/25°, voxel size = 0.96 × 0.96 × 2.5 mm3, and
bandwidth = 145 Hz/pixel), an axial 3D T2W TSE sequence (TR/TE/
α = 6591.4/80 ms/90°, voxel size = 0.92 × 0.92 × 2.5 mm3, and
bandwidth = 202 Hz/pixel), and a sagittal T2W (TR/TE/α = 2000/
90 ms/90°, voxel size = 0.89 × 0.89 × 3.0 mm3, and band-
width = 202 Hz/pixel).
2.D.2 | Simulating bladder and rectal status changes
Across all three imaging platforms, scans were acquired with a con-
stant bladder volume of 250 mL and varying inputted rectal volumes
(30, 60, 90, 120, and 150 mL). In the MR‐SIM, additional scans were
acquired with a constant rectal volume of 60 mL and varying bladder
volumes (90, 150, 250, and 350 mL) ranging from a mostly empty
bladder to a mostly full bladder. The fixed rectal and bladder vol-
umes of 60 and 250 mL, respectively, were selected as prostate can-
cer treatments that are ideally simulated/delivered with a mostly
empty rectum and mostly full bladder.19 Organ visibility was qualiti-
tatively evaluated for each imaging modality. Rectum and bladder
volumes were delineated on CT‐SIM and MR‐SIM T2W datasets in
MIM Maestro (MIM Software. Inc, Beachwood, OH) to analyze filling
accuracy, defined as the difference between expected and measured
volumes.
2.D.3 | Organ interactions
Contours were generated for the bladder, rectum, and prostate on
all MR‐SIM T2W datasets in MIM. Centroid displacements due to
volume changes were assessed for each contoured organ. Bladder
and rectum diameters [left–right (L‐R) and anterior–posterior (A‐P)]
were measured with increased bladder and rectum filling to assess
shape changes due to differing filling conditions. Associations
between bladder and rectum volumes and resulting centroid dis-
placements were assessed via linear regression.
2.D.4 | Reproducibility tests
To assess the reproducibility of organ filling, repeated measures
were conducted for rectal volumes of 30 and 60 mL for the CT‐SIM
and MR‐linac with a fixed bladder volume of 250 mL. Repeated mea-
sures of rectal and bladder volumes of 30 and 250 mL, respectively,
were obtained in the MR‐SIM. Reproducibility was assessed by con-
touring organs in MIM and analyzing the centroid and volume differ-
ences over repeated trials.
2.E | Treatment plan and dosimetry verification
A CT‐SIM was performed with bladder and rectum volumes of 250
and 90 mL, respectively. Isocenter was set to the center of the sili-
cone sponge prostate. The bladder, rectum, and prostate, which
were set as the gross tumor volume (GTV), were manually contoured
in the ViewRay treatment planning system (TPS) (ViewRay Inc., Oak-
wood Village, OH). To ensure the chamber location was not in a
high‐dose gradient region, a 2.5‐cm margin in the posterior direction,
and 1.0‐cm margin in all other directions were added to the GTV to
generate a pseudo-planning target volume (PTV). An 11‐field IMRT
6X Flattening Filter Free (FFF) MR‐Linac treatment plan was gener-
ated on the CT dataset using a Monte Carlo dose calculation
algorithm based on VMC++8 in the ViewRay TPS. Fifty step‐and‐
shoot segments were used for a total MU of 756.5 and a target
dose constraint of 78 Gy to 95.00% of the PTV, delivered in
39 × 2 Gy fractions. After CT‐SIM, the phantom was setup to
scribes on the MR‐Linac, localized with a 173 s, 45 × 30 × 36 cm3
FOV, and 0.15 × 0.15 cm2 resolution TrueFISP MRI sequence.
Couch corrections determined during localization were applied. A
point dose measurement was acquired between the prostate and
rectum using an MR‐compatible A12 Exradin ion chamber (Standard
Imaging Inc., Middleton, WI) and compared to the TPS.
3 | RESULTS
3.A | Phantom geometry
Table 1 best summarizes the average dimensions of the male pelvis
habitus and pelvic skeleton geometry measured from the 19‐patient
cohort. The final male pelvis phantom external acrylic casing was
38.1 cm wide (4.3% less than expected) and 23.0 cm tall. The final
phantom skeletal structure greater trochanter width had the largest
percent difference (11.2%) from the desired values. However, all
skeletal dimensions were within the range of measurements taken
from the patient population data.
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3.B | Internal organ kinematics
To quantify internal status changes, bladder filling data from 10
human subjects yielded an average bladder volume difference of
87% between empty (81.9 ± 66.9 mL) and full (383.0 ± 346.7 mL)
bladders. Figure 1 shows a 3D rendering of the volumetric bladder
and rectum at each time point for a representative case, highlighting
the large longitudinal displacement between initial and final bladder
volumes. Bladder centroids translated 13.2 ± 11.7 mm superiorly,
1.7 ± 7.5 mm anteriorly, and 1.4 ± 4.2 mm laterally (left) over the
cohort. On average, rectum centroids moved 1.7 ± 10.7 mm superi-
orly, 1.2 ± 2.8 mm posteriorly, and 0.2 ± 1.0 mm laterally (left). Fig-
ure 2(a) demonstrates the position and growth of the bladder and
rectum over time for three of the subjects who participated in the
bladder filling study. Rectal volumes ranged between 30 and 270 mL
(105 ± 65 mL). The results for the width and length of the rectum
contour as well as the distance from the coccyx to the posterior of
the rectum are shown in Fig. 2(b). The rectum yielded the largest
increase in width in its center between the initial and final time
points, demonstrating that a balloon with a larger length than width,
and with a wide central axis was needed to simulate the rectum. A
coccyx to posterior rectum distance of approximately 5 cm was rec-
ommended for rectal balloon placement within the phantom.
3.C | Phantom materials
3.C.1 | Bladder considerations
The silicone and polyisoprene balloons were filled to a maximum vol-
ume of 250 and 350 mL of distilled water, respectively, without
bursting. After one filling cycle, the polyisoprene balloon showed
slight deterioration and mechanical changes. The silicone balloon
was more robust during filling experiments, suggesting that it would
be good for long‐term use within the phantom. The silicone balloon
was filled to >380 mL with little to no air bubbles present. There-
fore, the silicone balloon was chosen for use within the phantom as
it addressed the concern of deterioration of polyisoprene over time
with exposure to water and oxygen and was able to achieve the
desired volumes. Additionally, silicone, in terms of electron density
and MR signal is a suitable substitute material for exterior organ
shells.15 The barbed fitting used to tether the balloon to the catheter
at each end withstood balloon pressure at maximum volume.
3.C.2 | Bone considerations
Both mold‐cast pelvises had anthropomorphic shapes, but the clear
urethane pelvis structure did not include femoral heads and was
>12% different than desired in pelvic width and depth. The clear
pelvis also had a CT number of 60 HU, which is considerably less
than the CT number of cancellous bone (262 HU).20 The blue dyed
urethane pelvis included femoral heads, was appropriately sized, and
exhibited a CT number closer to that of cancellous bone (213 HU).
Neither pelvis generated a signal in MRI sequences, particularly in
the UTE acquisition, and neither approximated cortical bone
(1454 HU).20 Nevertheless, the blue urethane was selected for the
initial phantom build due to its higher CT number.
3.D | Phantom build
The final phantom build is shown Figs. 3(a)–3(c), with average male
pelvic anatomy (height/width = 23.0/38.1 cm). Final material candi-
dates were as follows: 300‐mL silicone balloons for the bladder
(#BM‐300‐2), and rectum (#BM‐300‐3), and blue dyed urethane
(PT8957) for the pelvic structure. Each balloon was tethered at both
ends (axially) by their catheter to the pelvic structure by thin silicone
rubber chord to prevent them from floating freely throughout the
phantom. The bladder and phantom habitus were filled with distilled
water doped with 7 and 15 mg/L concentrations of Mn2+ (as
MnCl2:4H2O) to achieve a relaxation time of ~900 ms (urine) and
~300 ms (fat/muscle), respectively. Figure 3(c) highlights the bladder
and rectal filling assembly consisting of two 400‐mL syringes used to
induce bladder volume changes, a 140‐mL syringe used to fill the
rectum with air, and a 1000‐mL flexible reservoir (Hydrapak, Oak-
land, CA) that can be easily removed via quick connect/disconnect
fittings. The expansion device filled with the same concentration
[15 mg/L of Mn2+ (as MnCl2:4H2O))] of distilled water as the phan-
tom habitus was used to account for water displacement caused by
TAB L E 1 Patient population and final phantom pelvic habitus and skeleton dimensions.
Measurement Patient population dimensions (cm) mean ± SD (range) Final phantom dimension (cm) Percent difference
Body width (left–right) 36.5 ± 1.9 (33.6–40.0) 38.1 4.3
Body height (anterior–posterior) 23.0 ± 1.4 (21.2–25.6) 23.0 0
Sacrum—external Spacing 1.6 ± 0.4 (1.0–2.2) 1.6 0
Iliac crest width 25.5 ± 2.1 (22.8–28.8) 27.2 6.4
Femoral head width 22.2 ± 1.3 (20.0–25.5) 23.5 5.7
Greater trochanter width 30.2 ± 1.6 (26.9–34.4) 33.8 11.2
Pelvic depth 14.7 ± 1.0 (12.8–17.0) 14.2 3.5
Pelvic height 20.9 ± 1.4 (17.4–23.4) 20.8 0.5
Values are given as a mean of the prostate patient population (n = 19).
SD, standard deviation.
Percent difference calculated between the mean of the patient population dimensions and final phantom dimensions.
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varying internal volumes, to decrease internal pressure on the phan-
tom casing, and also to reduce the amount of air bubbles.
A quarter‐inch‐thick polyvinyl alcohol (PVA) open cell sponge
was inserted between the bladder and rectum to systematically
tether them together and mimic connective tissue. A silicone sponge
was formed into a cylindrical shape to represent the prostate with a
central hole for the 4‐mm‐inner diameter and 7‐mm‐outer diameter
silicone rubber tubing bladder catheter (urethra). Three ~10‐cm‐dia-
meter removable end caps were added to the exterior of the phan-
tom to enable access for modular changes such as inserting
dosimetry equipment and substituting organs while the skeletal
structure is rigidly affixed. Figure 3(d) highlights interchangeable end
caps designed to fit MR‐compatible A12 and A26 Exradin ion cham-
bers. Additional dosimetry inserts to accommodate MR‐compatible
chambers and a 2″ × 2.5″ film cassette can also be utilized.
3.E | Phantom evaluation
3.E.1 | Simulating bladder and rectal status changes
Sagittal views of the CT‐SIM datasets at inputted rectal volumes (30,
90, and 150 mL) are shown in Fig. 4(a). The rectum, urethra, bone,
and phantom filling exhibited contrasts as expected for these tissue
types. However, the bladder was almost indistinguishable from sur-
rounding material and was very difficult to visualize in the CT‐SIM
images. Delineated rectal volumes differed by a maximum of 14%
(<5 mL) from the expected rectal volume of 30 mL. Overall, a differ-
ence of 3.3 ± 7.0% (0.6 ± 3.8 mL) was obtained over all rectal vol-
umes with excellent agreement between expected volumes and
delineated volumes.
Figure 4(b) shows the sagittal TrueFISP MR‐Linac images for
increasing rectal volumes. In this modality, the bladder was slightly
darker than background and easier to distinguish. The open cell
silicone sponge prostate changed proton density to give MR contrast
and was visible just beneath the bladder. As expected, the rectal air
and pelvic bones generated no MR signal, rendering the organ
boundaries indistinguishable from each other. As a result, a quarter‐
inch‐thick PVA sponge was inserted between the pelvis and rectum
to introduce a barrier and differing contrast for future imaging stud-
ies. This modification was possible due to the modular design of the
phantom allowing the phantom interior to be retrofitted when
needed.
The T1W and T2W MR‐SIM images are shown in Figs. 4(c) and
4(d) for rectal volumes of 30, 90, and 150 mL. The PVA sponge suc-
cessfully generated a barrier to differentiate between the rectum
and bones in the T1W and T2W images. The expected T1W con-
trast (darker bladder, brighter background) and T2W contrast
(brighter bladder, darker background) were observed in the MR‐SIM
sequences. Axial views of the T1W and T2W datasets for increasing
bladder volumes (90, 150, 250, and 350 mL) are shown in Figs. 5(a)
and 5(b). Delineated bladder volumes differed by a maximum of 11%
(10 mL) from the expected bladder volume of 90 mL. Across all blad-
der volumes, an overall difference of 3.1 ± 5.6% (2.5 ± 6.4 mL) was
obtained with excellent agreement between expected and measured.
3.E.2 | Organ interactions
With increasing rectal volumes, both the bladder‐ and prostate‐simu-
lated organs translated in the anterior direction as highlighted by the
MR‐Linac and MR‐SIM sagittal images in Figs. 4(b)–4(d). Negligible
centroid shifts (<2.5 mm) were observed in the superior–inferior (S‐I)
and L‐R directions. The scatter plot shown in Figs. 6(a) and 6(b) sum-
marizes the A‐P bladder and prostate centroid displacements for
increasing rectal volumes. The bladder and prostate translated 18.5
and 4.5 mm toward the anterior of the phantom between initial
(a) (b)
(c) (d)
F I G . 3 . Final phantom build: (a) Sagittal
and (b) coronal view, where the bladder
(Bl) and rectum (R) are represented by the
chosen silicone balloon and the prostate
(P) by a cylindrical silicone sponge. (c) Four
devices (2 × 400 mL syringe, 140‐mL
syringe, and 1000‐mL flexible reservoir)
used to induce bladder and rectal status
changes. (d) Two replaceable endcaps that
allow for the A12 and A26 Exradin MR‐
compatible ion chambers to be inserted
into the phantom and their corresponding
inserts, as well as the film cassette.
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(30 mL) and final (150 mL) rectal volumes, respectively. Strong, nega-
tive associations (R2 = 0.94–0.98, P < 0.01) were observed between
increasing rectal volumes and bladder A‐P and prostate A‐P displace-
ment. Between the initial (30 mL) and final (150 mL) rectal volumes,
a 6‐mm reduction in bladder width (A‐P) at the centroid location was
observed due to the compression induced on the bladder with
increased rectal volume.
Figures 6(c) and 6(d) best summarize the A‐P centroid displace-
ments for the rectum and prostate in response to bladder filling. The
prostate translated 2.4 mm toward the phantom anterior between
initial and final bladder volumes (90 and 350 mL, respectively),
where a strong, negative correlation (R2 = 0.98, P = 0.0075) was
observed between prostate displacement (A‐P) and increasing
bladder volumes. Negligible prostate centroid displacements
(<1.5 mm) were observed in the S‐I and L‐R directions with
increased bladder size. With increased bladder volumes, minimal rec-
tal displacements were observed in the A‐P direction (<3 mm),
whereas negligible rectum centroid displacements were observed in
the S‐I and L‐R directions (<1.5 mm). However, Fig. 5 highlights that
increasing the bladder volume from 90 to 350 mL resulted in a cor-
responding rectal compression in the A‐P direction. A 9‐mm
decrease (A‐P) and 6‐mm increase (L‐R) in the rectum width was
observed.
3.E.3 | Reproducibility tests
Sagittal views of the reproduced 30‐ and 60‐mL rectal volumes in
the MR‐Linac and CT‐SIM are shown in Figs. 7(a) and 7(b), where
similar rectal shapes were observed in each duplicated system. Vol-
ume changes observed in each reproduced volume trial are shown in
Fig. 7(c), where smaller rectal volumes were more challenging to
reproduce due to unpredictable balloon contraction/expansion with
small volumes. The reproduced 30‐mL (n = 3) and 60‐mL (n = 2) rec-
tum volumes exhibited 1.32 ± 0.49 and 0.36 ± 0.46 mm average
vector centroid changes and 5.00 ± 4.14 mL (~13.8%) and
1.53 ± 1.06 mL (~2.4%) volume differences, respectively, between
trials. In MR‐SIM, a reproduced bladder volume of 250 mL exhibited
a 1.6 mL (~0.6%) volume change and a 0.70‐mm centroid change
between trials.
3.F | Dosimetry verification
The MR‐SIM, CT‐SIM, and corresponding treatment plan calculated
on the CT‐SIM dataset are shown in Fig. 8. The ion chamber was
visible and contoured in MR‐SIM images. The PTV was expanded in
the posterior direction to ensure the ion chamber did not fall into a
high dose gradient region. The plan met all prescription and organ at
risk dose constraints. The measured point dose between the rectum
and prostate was 212.8 cGy, 1.5% different from the expected
216.0 cGy TPS dose at the chamber location.
4 | DISCUSSION
With the emergence of MR‐only treatment planning and MR‐IGRT,
the need exists to develop an MR‐compatible pelvic phantom that is
sophisticated enough to benchmark the uncertainties introduced in
these workflows. An anthropomorphic and modular end‐to‐end pel-
vis phantom was designed and evaluated, with the ability to simulate
accurate and reproducible bladder and rectal physiological status
conditions. Additionally, the modularity of the phantom permits the
ability to perform dosimetric validation using both point and film‐
based dosimetry options.
This work introduced several added features to the currently
available MR‐compatible pelvic phantoms. Sun et al. incorporated
solid polymethylmethacrylate (PMMA) structures to represent the
(a)
(b)
(c)
(d)
F I G . 4 . Increasing rectal volumes: sagittal view for increasing
rectum volumes (30, 90, and 150 mL) for (a) CT‐SIM, (b) MR‐Linac,
(c) T1W MR‐SIM, and (d) T2W MR‐SIM. The bladder (Bl), rectum (R),
prostate (P), and bone (Bo) are labeled in each modality.
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rectum and bladder that did not offer the ability to deform.14 As it
is more representative of the pelvic region to simulate anatomical
position variation due to volume variations in the rectum and blad-
der, PETE incorporated both a fluid‐fillable bladder and air‐fillable
rectum. Previously, Niebuhr et al. and Kadoya et al. incorporated
3D‐printed deformable bladders that accurately represented the
organs anatomically, but mechanical wear and tear resulted in
structures needing to be replaced frequently.15 Additionally, at
small volumes, the bladder did not deform well as substantial
amounts of air remained in the bladder.21 The silicone medical bal-
loons used in PETE to represent the bladder and rectum addressed
these concerns, as the bladder performed well at low volumes with
little presence of air and did not deteriorate rapidly with continued
use. A benefit of this design method is that one can simulate dif-
ferent physiological status changes at low and high volumes and
measure potential dosimetric and geometric variations that arise
due to anatomical structure position as a result of intrasession
bladder and rectal filling. The small volume and centroid changes
obtained from the accuracy and reproducibility studies suggest that
the robust phantom design allowed for precise and reliable repro-
duced organ states with little organ displacement at different time
points. The phantom was also able to induce organ shape changes
and displacements, respectively, with increasing rectal and bladder
volumes.
F I G . 5 . Increasing bladder volumes: axial view for increasing bladder volumes (90, 150, 250, and 350 mL) for (a) T1W MR‐SIM and (b) T2W
MR‐SIM. The bladder (Bl), rectum (R), and bone (Bo) are labeled.
F I G . 6 . Centroid displacements: (a) bladder and (b) prostate anterior–posterior centroid displacement with increasing rectal volume. (c)
Rectum and (d) prostate anterior–posterior centroid displacement with increasing bladder volumes.
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Additionally, previous pelvic phantoms offered limited dosimetry
options such as optically stimulated luminescent dosimeters (OSLD).
Our phantom was designed to enable dosimetric verification of
treatment plans via compatibility with MR‐compatible ion chambers,
with a dosimetric point dose agreement to <1.5% from expected for
an A12 ion chamber. Due to the modular design and endcaps, the
insertion of Gafchromic film for planar dose verification or A26 small
ion chamber can be explored in future work. Other future work can
include incorporating inserts to include OSLDs or a 3D‐printed hol-
low shelled deformable prostate surrogate as opposed to the cylin-
drical silicone prostate. This prostate volume may be filled with
either a doped agarose gel15 that exhibits similar MR signal genera-
tion properties (T1 = 1317 ± 85 ms and T2 = 88 ± 0 ms at 1.5 T)22
as the prostate or a gel with dosimetric properties. Gel dosimetry
has shown promise for measuring 3D dose distributions23 and may
prove useful within the prostate casing.
A major obstacle with MR‐compatible phantoms is simulating
skeletal anatomy with materials that accurately generate tissue
specific signal in MRI. Sun et al., was able to represent the low MR
signal intensity of the femoral heads by filling spherical PMMA struc-
tures.14 However, they did not incorporate a structure to represent
the rest of the skeletal anatomy. Niebuhr et al. used a 3D‐printed
hollow bone case filled with a combination of Vaseline and K2HPO4
to accurately represent inner bone.15 This method generated the sig-
nal intensity of inner and outer bone in MRI but lacked the attenua-
tion properties of outer bone in CT. More recently, Soliman et al.
used a human skull in a realistic head phantom, which was advanta-
geous as it depicted the properties of cortical bone in UTE
sequences that are difficult to simulate.24 The skeletal anatomy in
PETE was represented by a blue dyed urethane pelvis that was
unable to generate the MRI signal characteristics of human cortical
bone. However, Rai et al. has identified a 3D printable solid resin
material that has similar signal properties to cortical bone in UTE
MRI sequences.25 This resin material has been successfully used to
replicate skeletal anatomy in other phantoms and may prove useful
in future generations of the PETE phantom. Adoption of this resin
into a new 3D printed pelvic skeleton structure may improve syn-
thetic CT generation and dose calculation performed in an MR‐only
workflow.
Additional limitations exist in the phantom design, including only
considering male anatomy for phantom and organ geometry. Male
anatomy was simulated as the MR‐only RT is FDA approved or CE
F I G . 7 . Reproduced sagittal volumes: (a)
MR‐Linac 30 mL and (b) CT‐SIM 60 mL
datasets for reproduced rectum trials. (c)
Volume changes for the bladder and
rectum from trials 1 and 2 of duplicated
rectal volumes in each modality, with the
corresponding percent volume changes.
F I G . 8 . Treatment plan: axial and sagittal views of the CT‐SIM,
0.35 T MR‐SIM, and dose for an 11‐field IMRT 6XFFF MR‐Linac
treatment plan at the same slice in the phantom. Contours of the
bladder (green), rectum (blue), gross tumor volume (pink), planned
target volume (red), and ion chamber (yellow) are shown. The
chamber is not delineated in the MR‐SIM to highlight its visibility for
localization.
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marked and in clinical use for the treatment of prostate cancer.26,27
While the modular phantom does enable the introduction of 3D
printed organs for female anatomy (uterus, cervix, etc.), as other
deformable phantoms have,21 the current pelvic skeleton geometry
does not accurately represent the average female anatomy. The pel-
vis structure was modeled after the male pelvis, which is taller and
narrower than the female pelvis, with a 7% difference in width to
height ratios.28 Future extensions of this work include incorporating
a penile bulb and reorganization of internal organs so that the rec-
tum interacts more closely with the prostate.
Despite some of the above limitations, a novel, anthropomorphic,
and modular pelvic phantom with the ability to simulate bladder and
rectal status changes was developed and validated. Potential future
clinical applications of this phantom include the benchmarking of
MR-to-MR deformable image registration algorithms, evaluation of
MR‐based adaptive workflows, quantifying distortions in MR images
due to susceptibility effects at air‐tissue interfaces, and evaluating
the electron return effect for MR‐IGRT.
5 | CONCLUSION
A novel end‐to‐end pelvis phantom has been developed to validate
MR‐only and MR‐IGRT workflows, with the ability to perform both
dosimetric and geometric evaluations.
ACKNOWLEDGMENTS
Research reported in this publication was supported in part by a
Henry Ford Health System grant and the National Cancer Institute
of the National Institutes of Health under award number:
R01CA204189. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health.
CONFLICTS OF INTEREST
The submitting institution holds research agreements with Philips
Healthcare, ViewRay Inc., and Modus Medical Devices.
REFERENCES
1. Khoo VS, Dearnaley DP, Finnigan DJ, et al. Magnetic resonance
imaging (MRI): considerations and applications in radiotherapy treat-
ment planning. Radiother Oncol. 1997;42:1–15.
2. Hentschel B, Oehler W, Strauß D, Ulrich A, Malich A. Definition of
the CTV prostate in CT and MRI by using CT–MRI image fusion in
IMRT planning for prostate cancer. Strahlenther Onkol.
2011;187:183–190.
3. Rasch C, Barillot I, Remeijer P, et al. Definition of the prostate in CT
and MRI: a multi‐observer study. Int J Radiat Oncol Biol Phys.
1999;43:57–66.
4. Wachter S, Wachter-Gerstner N, Bock T, et al. Interobserver com-
parison of CT and MRI‐based prostate apex definition clinical rele-
vance for conformal radiotherapy treatment planning. Strahlenther
Onkol. 2002;178:263–268.
5. Milosevic M, Voruganti S, Blend R, et al. Magnetic resonance imag-
ing (MRI) for localization of the prostatic apex: comparison to com-
puted tomography (CT) and urethrography. Radiother Oncol.
1998;47:277–284.
6. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delin-
eation variation using CT versus combined CT + MRI in intensity–
modulated radiotherapy for prostate cancer. Strahlenther Onkol.
2005;181:424–430.
7. Roberson PL, McLaughlin PW, Narayana V, et al. Use and uncertain-
ties of mutual information for computed tomography/magnetic reso-
nance (CT/MR) registration post permanent implant of the prostate.
Med Phys. 2005;32:473–482.
8. Korsager AS, Carl J, Østergaard LR. Comparison of manual and auto-
matic MR‐CT registration for radiotherapy of prostate cancer. J Appl
Clin Med Phys. 2016;17:294–303.
9. Nyholm T, Nyberg M, Karlsson MG, Karlsson M. Systematisation of
spatial uncertainties for comparison between a MR and a CT‐based
radiotherapy workflow for prostate treatments. Radiat Oncol.
2009;4:54.
10. Noel CE, Parikh PJ, Spencer CR, et al. Comparison of onboard low‐
field magnetic resonance imaging versus onboard computed tomog-
raphy for anatomy visualization in radiotherapy. Acta Oncol.
2015;54:1474–1482.
11. Fischer-Valuck BW, Henke L, Green O, et al. Two‐and‐a‐half‐year
clinical experience with the world's first magnetic resonance image
guided radiation therapy system. Adv Radiat Oncol. 2017;2:485–493.
12. Schmidt MA, Payne GS. Radiotherapy planning using MRI. Phys Med
Biol. 2015;60:R323–R361.
13. Kim J, Glide-Hurst C, Doemer A, et al. Implementation of a novel
algorithm for generating synthetic CT images from magnetic reso-
nance imaging data sets for prostate cancer radiation therapy. Int J
Radiat Oncol Biol Phys. 2015;91:39–47.
14. Sun J, Dowling J, Pichler P, Menk F. MRI simulation: end‐to‐end
testing for prostate radiation therapy using geometric pelvic MRI
phantoms. Phys Med Biol. 2015;60:3097–3109.
15. Niebuhr NI, Johnen W, Güldaglar T, et al. Technical note: radiological
properties of tissue surrogates used in a multimodality deformable
pelvic phantom for MR‐guided radiotherapy. Med Phys.
2016;43:908–916.
16. Radiation Therapy Oncology Group. RTOG 0815: A Phase III Prospec-
tive Randomized Trial of Dose-Escalated Radiotherapy with or without
Short-Term Androgen Deprivation Therapy for Patients with Intermedi-
ate-Risk Prostate Cancer. https://www.rtog.org/ClinicalTrials/Protoc
olTable/StudyDetails.aspx?study=0815. Accessed January 15, 2018.
17. Gatehouse PD, Bydder GM. Magnetic resonance imaging of short
T2 components in tissue. Clin Radiol. 2003;58:1–19.
18. Chavhan GB, Babyn PS, Jankharia BG, Cheng H-LM, Shroff MM.
Steady‐state MR imaging sequences: physics, classification, and clini-
cal applications. Radiographics. 2008;28:1147–1160.
19. Wen N, Glide-Hurst C, Nurushev T, et al. Evaluation of the deforma-
tion and corresponding dosimetric implications in prostate cancer
treatment. Phys Med Biol. 2012;57:5361–5379.
20. Schneider W, Bortfeld T, Schlegel W. Correlation between CT num-
bers and tissue parameters needed for Monte Carlo simulation of
clinical dose distributions. Phys Med Biol. 2000;45:459–478.
21. Kadoya N, Miyasaka Y, Nakajima Y, et al. Evaluation of deformable
image registration between external beam radiotherapy and HDR
brachytherapy for cervical cancer with a 3D‐printed deformable pel-
vis phantom. Med Phys. 2017;44:1445–1455.
22. Bazelaire CMJD, Duhamel GD, Rofsky NM, Alsop DC. MR imaging
relaxation times of abdominal and pelvic tissues measured in vivo at
3.0 T: preliminary results. Radiology. 2004;230:652–659.
23. De Deene Y, De Wagter C, Van Duyse B, et al. Three‐dimensional
dosimetry using polymer gel and magnetic resonance imaging
274 | CUNNINGHAM ET AL.
applied to the verification of conformal radiation therapy in head‐
and‐neck cancer. Radiother Oncol. 1998;48:283–291.
24. Soliman AS, Burns L, Owrangi A, et al. A realistic phantom for vali-
dating MRI‐based synthetic CT images of the human skull. Med Phys.
2017;44:4687–4694.
25. Rai R, Manton D, Jameson MG, et al. 3D printed phantoms mimick-
ing cortical bone for the assessment of ultrashort echo time mag-
netic resonance imaging. Med Phys. 2018;45:758–766.
26. Tyagi N, Fontenla S, Zelefsky M, et al. Clinical workflow for MR‐only
simulation and planning in prostate. Radiat Oncol. 2017;12:119.
27. Siversson C, Nordström F, Nilsson T, et al. Technical note: MRI only
prostate radiotherapy planning using the statistical decomposition
algorithm. Med Phys. 2015;42:6090–6097.
28. Brinckmann P, Hoefert H, Jongen HT. Sex differences in the skeletal
geometry of the human pelvis and hip joint. J Biomech.
1981;14:427–430.
CUNNINGHAM ET AL. | 275
